Which labs should be checked before and after starting a statin, including fasting lipid panel, liver enzymes (alanine aminotransferase and aspartate aminotransferase), creatine kinase if indicated, basic metabolic panel (serum creatinine and estimated glomerular filtration rate), fasting glucose or hemoglobin A1c if at diabetes risk, and thyroid‑stimulating hormone if hypothyroidism is suspected?

Laboratory Monitoring for Statin Therapy

Obtain baseline liver transaminases (ALT/AST) before starting a statin, but routine follow-up liver enzyme and creatine kinase monitoring is NOT recommended unless the patient develops symptoms suggesting hepatotoxicity or severe muscle symptoms. 1

Pre-Statin Laboratory Testing

Before initiating statin therapy, you should obtain:

• Baseline liver transaminases (ALT and AST) - This establishes a reference point but is primarily to identify pre-existing liver disease rather than predict statin toxicity 1
• Fasting lipid panel - Essential for establishing baseline LDL-C and monitoring treatment efficacy
• Consider additional baseline tests based on individual risk factors:
  • Fasting glucose or HbA1c if diabetes risk factors are present (metabolic syndrome, obesity, family history) 1
  • TSH if hypothyroidism is suspected (can cause secondary dyslipidemia and myopathy)
  • Baseline creatinine/eGFR for renal function assessment

Do NOT routinely measure baseline CK unless the patient has pre-existing muscle symptoms, objective weakness, or significant risk factors for myopathy 1.

Post-Statin Laboratory Monitoring

What NOT to Do (Critical Pitfall)

Routine monitoring of liver enzymes and CK after statin initiation is explicitly NOT recommended 1. The 2018 ACC/AHA guidelines clearly state that routine measurements are "not useful" because:

• Severe hepatotoxicity is rare and not prevented by routine monitoring 1
• Asymptomatic transaminase elevations (even >3× ULN) are infrequent and often resolve with dose adjustment 1
• Multiple studies show minimal clinical yield from routine screening 2, 3
• The FDA removed requirements for routine post-statin liver enzyme testing from drug labels 4

When to Measure Labs After Starting Statins

Only measure labs when clinically indicated:

1. Liver enzymes (ALT, AST, plus total bilirubin and alkaline phosphatase):

   • If patient develops symptoms suggesting hepatotoxicity (jaundice, dark urine, right upper quadrant pain, unexplained fatigue) 1
   • NOT for asymptomatic patients on routine follow-up

2. Creatine kinase:

   • Only if patient develops severe muscle symptoms (not mild myalgias) 1
   • If objective muscle weakness is present 1
   • NOT for routine screening or mild muscle aches

3. Lipid panel:

   • Repeat at appropriate intervals (typically 4-12 weeks after initiation, then periodically) to assess treatment efficacy and guide dose adjustments
   • This is the only routine lab that should be monitored

4. Glucose/HbA1c:

   • In patients at increased diabetes risk, monitor as clinically appropriate
   • If new-onset diabetes develops, continue the statin while emphasizing lifestyle modifications 1

Management of Abnormal Results

Elevated Transaminases

• If ALT/AST >3× ULN: Evaluate for non-statin causes (alcohol, viral hepatitis, NAFLD, medications, autoimmune disease) 1
• Often resolves with dose reduction or switching to alternative statin 1
• Statins are NOT contraindicated in chronic stable liver disease (including NAFLD) and may provide benefit 1, 5

Elevated CK with Severe Symptoms

• Assess for reversible causes (hypothyroidism, vitamin D deficiency, drug interactions) 1
• Consider statin-associated autoimmune myopathy if marked persistent CK elevation with weakness and incomplete resolution after discontinuation 1
• Most patients can tolerate rechallenge with alternative statin or modified dosing 1

Key Clinical Pearls

• The vast majority of muscle symptoms are subjective myalgias without CK elevation - these do not require lab testing 1
• Recent evidence shows that absent CK testing when transaminases are elevated may miss 3.6% of patients with biochemical myopathy, potentially leading to unnecessary GI referrals 6 - but this still doesn't justify routine screening
• The cardiovascular benefits of statins far outweigh the risks of new-onset diabetes or mild transaminase elevations 1
• Pre-treatment counseling about potential side effects is more important than routine lab monitoring 1